LoadSpring Collaborates with Google Cloud and SADA to Deliver Enhanced AI Solutions
10.12.2020 19:27:00 EET | Business Wire | Press release
LoadSpring Solutions, a leading provider of global managed cloud solutions, announces a strategic collaboration with Google Cloud and SADA to provide clients with enhanced project analytics via Artificial Intelligence and Business Intelligence solutions. LoadSpring will combine its application, support, and project expertise with SADA's delivery expertise and Google Cloud infrastructure, solutions, and capabilities in AI and ML to help clients eliminate risks while increasing their insights and data access to make critical business and project decisions in real-time.
As a global leader in hosting, integrating, and providing access to software application data for project and asset-intensive organizations, LoadSpring recognizes the importance of access to a global technology footprint. Its customers operate worldwide and expect the same performance and support, whether in the Americas, Europe, the Middle East, or Pan-Asia. The new alliance will accelerate customer benefits, including one-stop managed cloud services, centralized support, and improved project command and control through LoadSpring Cloud Platform.
"The strategic alignment between our organizations is significant. The investments Google Cloud, SADA, and LoadSpring, are making to deliver best-in-class cloud solutions is transformational for our clients. I'm truly excited about the prospect of hosting, accessing, and leveraging years of data during the project life-cycle," said Dean Edmundson, Chief Strategy Officer at LoadSpring.
"Organizations today have an opportunity to transform business processes and derive more value out of their data with cloud capabilities in AI, ML, and analytics," said Dave Hutchison, Managing Director, Worldwide Channels at Google Cloud. "We are excited that LoadSpring and SADA will collaborate to help businesses leverage Google Cloud infrastructure and technologies to do so, and look forward to working together to drive digital transformation."
"We're excited to partner with LoadSpring to help them maximize the value of their Google Cloud investment," stated Simon Margolis, VP of CE, SADA. "The combined strength of our offerings will help clients expand their cloud, Business Intelligence, AI, and ML capabilities to achieve better project results."
ABOUT LOADSPRING
Founded in 1999, LoadSpring is a global cloud solutions provider obsessed with offering the highest level of managed cloud services. LoadSpring delivers expert Project Management solutions and fast access to project data, Business Intelligence, and hundreds of best-of-breed project-based applications. Data safety is assured through their SOC 2 Type II security certification, providing an impenetrable cloud environment. Through their proprietary LoadSpring Cloud Platform and their soon-to-be-launched LoadSpring Marketplace, customers and partners get effortless app provisioning, higher productivity, and ROI – all while reducing the burden on their IT departments.
ABOUT SADA
SADA is a leading global provider of business and technology services empowering people to transform their work, their organizations, and the world. SADA teams have helped enterprise clients in healthcare, media, entertainment, retail, manufacturing, and the public sector achieve their boldest ambitions and solve their most complex problems. A Google Cloud Partner with multiple Specializations, SADA delivers continuous innovation, strong partnerships, and service excellence. This has led to numerous accolades and awards, including the Google Cloud Global Reseller Partner of the Year for 2018 and 2019, the Inc. 5000 Honoree list of America's Fastest Growing Private Companies for 14 straight years, and the 2020 Inc. list of America's Top 50 Workplaces. More info at www.sada.com.
For more information, contact Stacey Witt at switt@loadspring.com or visit www.loadspring.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005791/en/
Contact information
Stacey Witt
switt@loadspring.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom